Preventing heart disease and Alzheimer's: why lowering LDL before age 40 matters most

Modern preventive medicine now possesses the tools to avoid cardiovascular disease, yet the decisive factor is deploying them decades before clinical risk becomes apparent. Michael Davidson, a cardiologist, articulates an argument that meets resistance in younger patients: those at 30 must begin modulating LDL levels today, not wait until 50 or 60 when arterial damage is already advanced. The logic is straightforward but countercultural: atherosclerosis is a cumulative process starting in youth and accelerating with age, especially in APOE4 carriers, the genotype carrying highest Alzheimer's risk. New therapeutics—from next-generation statins to PCSK9 inhibitors and emerging molecules—offer unprecedented precision for optimizing cholesterol in seemingly low-risk populations. For the Spanish biohacker or clinician reader, this means rethinking lipid screening as a longevity tool, not as a late-stage diagnostic marker of established disease.